Venture-Backed Biotech Firm Files $86M IPO In Stalled Market
Keros Therapeutics Inc., a venture-backed biotechnology firm developing therapies for hematological and musculoskeletal disorders, filed an $86 million initial public offering amid a dormant IPO market stalled by market turbulence and...To view the full article, register now.
Already a subscriber? Click here to view full article